


# Inhibiting mechanotransduction as a novel approach for oncology therapy

Mamatha Bangalore Nijaguna<sup>1</sup>, Ignacio Viciano Gonzalo<sup>1</sup>, Anabel-Lise Le Roux<sup>1</sup>, Pere Roca-Cusachs Soulere<sup>1,2</sup>

<sup>1</sup>Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Technology (BIST), Barcelona, Spain, <sup>2</sup>Universitat de Barcelona, Barcelona, Spain

## Introduction


- ❑ **Mechanotransduction** is a process of transmitting the mechanical cues to biochemical signals resulting in cellular function.
- ❑ Increased tissue stiffness are implicated in most solid tumors leading to deregulated mechanotransduction and drive disease progression.
- ❑ Currently, there are **no compounds or drugs** available that block mechanotransduction.



Tumour growth in breast cancer mouse model

Levental *et al.*, *Cell* 2009


## Background



Elosegui-Artola *et al.*, *Nat. Cell Biol.* 2016


Target unfolding opens **cryptic binding site** and upon interaction with binding partner cascade of events occur in a process called mechanotransduction. This interaction results in nuclear localization of **mechanosensitive transcription factor** implicated in tumor progression of several cancer types.

## Results




Cryo EM structure of target full length protein.

The target domain R3 is accessible for compound binding.




**Cytotoxicity assay:** C4 compound tested in target WT (B.) and KO (A.) cell line under soft and stiff conditions. AM2 compound tested in target WT and KO (C.) cell line in plastic surface. D. Table with IC50 values for indicated conditions



**Thermal shift assay:** Melting profile of WT protein (A.) and mechanically stable mutant protein (B.). (C.) 384-well plate data for WT protein depicting raw fluorescence (up) and derivative (down). D. Melting profile of WT protein with and without compounds. \*Inset table in each plot indicate mean Tm and std. deviation

## Project Concept



## Summary and outcome

### Deliverables:

- **First-in-class** mechanoinhibitor
- **Tool compound** to study mechanobiology
- High potential for **therapeutic applications in oncology** and other pathologies

### USP:

- **Novel concept** –mechanics in oncology
- Promising virtual screening hits- first **proof-of concept**
- Potentially compatible with other treatments
- Wide market in oncology

### Challenges:

- Interfere only with pathological pressures
- No comparable drugs for reference
- Currently, limited in funds

## References

- Northcott, J. M. *et al.* Feeling Stress: The Mechanics of Cancer Progression and Aggression. *Frontiers in cell and developmental biology*, 6, 17 (2018).
- Levental, K. R. *et al.* Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell*, 139(5), 891–906 (2009).
- Broders-Bondon F. *et al.* Mechanotransduction in tumor progression: The dark side of the force. *J Cell Biol* (2018).
- Elosegui-Artola, A. *et al.* Mechanical regulation of a molecular clutch defines force transmission and transduction in response to matrix rigidity. *Nat. Cell Biol* (2016).
- Elosegui-Artola, A. *et al.* Force Triggers YAP Nuclear Entry by Regulating Transport across Nuclear Pores. *Cell* (2017).

## Future directions



- ❑ Interested in collaboration with partners for chemical library and to conduct HTS for identification of mechanoinhibitors.
- ❑ Seeking funding opportunities for HTS and future development of identified hit to lead molecule.